Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

The Healthcare sector of the economy is front and center on Friday as shares of UnitedHealth drop 7.8%, spurring a widespread market selloff across the broader market a ...

While smokable product sales are declining slowly, sales of non-smokable products are driving growth for Altria Group. The company acquired the NJOY brand in 2023 and it's still one of just three ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

With 2025 underway, the AFS Health Care team highlights some of the most pressing legal issues facing the health care industry this year.